Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: Applicability to haemophilia A gene therapy

British Journal of Haematology

Volumn 104, Issue 1, 1999, Pages 27-36

  Gnatenko, Dmitri V ^a   Saenko, Evgueni L ^b   Jesty, Jolyon ^a   Cao, Liang Xian ^a   Hearing, Patrick ^a   Bahou, Wadie F ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b HOLLAND LABORATORY   (United States)

Author keywords

Coagulation; Factor VIII; Genetics; Haemostasis; Thrombosis

Indexed keywords

ASPARAGINE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DEOXYRIBONUCLEASE; GREEN FLUORESCENT PROTEIN; ISOLEUCINE; PHENYLALANINE; RECOMBINANT BLOOD CLOTTING FACTOR 8; SMALL NUCLEAR RNA; THREONINE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BLOOD CLOTTING TEST; CELL STRAIN COS1; CONTROLLED STUDY; DNA PACKAGING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HELA CELL; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; VIRUS CAPSID;

CELLS, CULTURED; DEPENDOVIRUS; DRUG DELIVERY SYSTEMS; FACTOR VIII; GENE DELETION; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA A; HUMANS; MUTATION;

EID: 0032958487     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01137.x     Document Type: Article

References (44)

1. Ach, R.A. & Weiner, A.M. (1987) The highly conserved U small nuclear RNA 3′-end formation signal is quite tolerant to mutation. Molecular and Cellular Biology, 7, 2070-2079.
2. Aledort, L., Levine, P., Hilgartner, M., Blatt, P., Spero, J., Goldberg, J., Bianchi, L., Desmet, V., Scheuer, P., Popper, H. & Berk, P. (1985) A study of liver biopsies and liver disease among hemophiliacs. Blood, 66, 367-372.
3. Bartlett, J.S., Sethna, M., Ramamurthy, L., Gowen, S.A., Samulski, R.J. & Marzluff, W.F. (1996) Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proceedings of the National Academy of Sciences of the United States of America, 93, 8852-8857.
4. Berns, K. & Giraud, C. (1996) Biology of adeno-associated virus. Adeno-Associated Virus (AAV) Vectors in Gene Therapy (ed. by K. I. Berns and C. I. Giraud), p. 1.
5. Cao, L.X. & Bahou, W.F. (1997) A green fluorescent protein/adeno-associated virus cell line for rapid characterization of gene transfer. (Abstract). Blood, 90, 410.
6. Clark, K.R., Voulgaropoulou, F., Fraley, D.M. & Johnson, P.R. (1995) Cell lines for the production of recombinant adeno-associated virus. Human Gene Therapy, 6, 1329-1341.
7. Connelly, S., Gardner, J.M., Lyons, R.M., McClelland, A. & Kaleko, M. (1996a) Sustained expression of therapeutic levels of human factor VIII in mice. Blood, 87, 4671-4677.
8. Connelly, S., Gardner, J.M., McClelland, A. & Kaleko, M. (1996b) High-level tissue-specific expression of functional human factor VIII in mice. Human Gene Therapy, 7, 183-195.
9. Connelly, S. & Kaleko, M. (1997) Gene therapy for hemophilia A. Thrombosis and Haemostasis, 78, 31-36.
10. Connelly, S., Mount, J., Mauser, A., Gardner, J.M., Kaleko, M., McClelland, A. & Lothrop, M., Jr (1996c) Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood, 88, 3846-3853.
11. Connelly, S., Smith, T.A., Dhir, G., Gardner, J.M., Mehaffey, M.G., Zaret, K.S., McClelland, A. & Kaleko, M. (1995) In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Human Gene Therapy, 6, 185-193.
12. Dong, J., Fan, P. & Frizzell, R.A. (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy, 7, 2101-2112.
13. Fallaux, F.J., Hoeben, R.C. & Briet, E. (1995) State and prospects of gene therapy for the hemophilias. Thrombosis and Haemostasis, 74, 263-273.
14. Foster, P.A., Fulcher, C.A., Houghten, R.A. & Zimmerman, T.S. (1988) An immunogenic region within residues Val670-Glu684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. Journal of Biological Chemistry, 263, 5230-5234.
15. Gnatenko, D., Arnold, T., Zolotukhin, S., Nuovo, G., Muzyczka, N. & Bahou, W. (1997) Characterization of recombinant adeno-associated virus-2 (AAV) as a vehicle for gene delivery and expression into vascular cells. Journal of Investigative Medicine, 45, 87-88.
16. Goedert, J., Kessler, C., Aledort, L., Biggar, R., Andes, W., White, G., Drummond, J., Vaidya, K., Mann, D., Eyster, M.E., Ragni, M., Lederman, M., Cohen, A., Bray, G., Rosenberg, P., Friedman, R., Hilgartner, M., Blattner, W., Kroner, B. & Gail, M. (1989) A prospective study of human immunodeficiency virus type I infection and the development of AIDS in subjects with hemophilia. New England Journal of Medicine, 321, 1141-1148.
17. Hernandez, N. (1985) Formation of the 3′ end of U1 and snRNA is directed by a conserved sequence located downstream of the coding region. EMBO Journal, 4, 1827-1837.
18. Herzog, R.W., Hagstrom, J.N., Kung, S.H., Tai, S.J., Wilson, J.M., Fisher, K.J. & High, K.A. (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America, 94, 5804-5809.
19. Hoyer, L.W. (1994) Hemophilia A. New England Journal of Medicine, 330, 38-47.
20. Kaufman, R.J., Wasley, L.C. & Dorner, A.J. (1988) Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. Journal of Biological Chemistry, 263, 6352-6362.
21. Kay, M.D., Rothenberg, S., Landen, C.N., Bellinger, D.A., Leland, F., Toman, C., Finegold, M., Thompson, A.R., Read, M.S., Brinkhous, K.M. & Woo, S.L.C. (1993) In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science, 262, 117-119.
22. 1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. Journal of Biological Chemistry, 266, 740-746.
23. Lund, E. & Dahlberg, J.E. (1984) True genes for human U1 small nuclear RNA. Journal of Biological Chemistry, 259, 2013-2021.
24. Lynch, C.M., Israel, D.I., Kaufman, R.J. & Miller, A.D. (1993) Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Human Gene Therapy, 4, 259-272.
25. McLaughlin, S.K., Collis, P., Hermonat, P.L. & Muzyczka, N. (1988) Adeno-associated virus general transduction vectors: analysis of proviral structures. Journal of Virology, 62, 1963-1973.
26. Miller, D.G., Adam, M.A. & Miller, A.D. (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Molecular and Cellular Biology, 10, 4239-4242.
27. Muzyczka, N. (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Current Topics in Microbiology and Immunology, 158, 98-129.
28. Pittman, D.D., Alderman, E.M., Tomkinson, K.N., Wang, J.H., Giles, A.R. & Kaufman, R.J. (1993) Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood, 81, 2925-2935.
29. Pittman, D.D. & Kaufman, R.J. (1993) Site-directed mutagenesis and expression of coagulation factors VIII and V in mammalian cells. Methods in Enzymology, 222, 236-237.
30. Rosenberg, J.B., Foster, P.A., Kaufman, R.J., Vokac, E.A., Moussalli, M., Kroner, P.A. & Montgomery, R.R. (1998) Intracellular trafficking of factor VIII to von Willebrand factor storage granules. Journal of Clinical Investigation, 101, 613-624.
31. Russell, D.W., Miller, A.D. & Alexander, I.E. (1994) Adeno-associated virus vectors preferentially transduce cells in S phase. Proceedings of the National Academy of Sciences of the United States of America, 91, 8915-8919.
32. Sadler, J.E. & Davie, E.W. (1987) Hemophilia A, hemophilia B, and von Willebrand's disease. The Molecular Basis of Blood Diseases (ed. by A. W. Nienhuis, P. Leder and P. W. Majerus), p. 575. Saunders, New York.
33. Saenko, E.L. & Scandella, D. (1995) A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. Journal of Biological Chemistry, 270, 13826-13833.
34. Saenko, E.L., Shima, M., Rajalakshmi, K.J. & Scandella, D. (1994) A role for the C2 domain of factor VIII in binding to von Willebrand factor. Journal of Biological Chemistry, 269, 11601-11605.
35. Sanger, F., Nicklen, S. & Coulsen, A. (1977) DNA sequencing with chain terminating inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 74, 5463-5467.
36. Scandella, D., Mattingly, M., deGraaf, S. & Fulcher, C.A. (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood, 74, 1618-1626.
37. Scandella, D., Timmons, L., Mattingly, M., Trabold, N. & Hoyer, L.W. (1992) A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thrombosis and Haemostasis, 67, 665-671.
38. Scharfmann, R., Axelrod, J.H. & Verma, I. (1991) Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proceedings of the National Academy of Sciences of the United States of America, 88, 4626-4630.
39. Snyder, R.O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winther, B., Meuse, L., Cohen, L.K., Thompson, A.R. & Kay, M.A. (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genetics, 16, 270-276.
40. Snyder, R.O., Xiao, X. & Samulski, R.J. (1996) Production of recombinant adeno-associated viral vectors. In: Current Protocols in Human Genetics (ed. by N. C. Dracopoli, J. L. Haines, B. R. Korf, D. T. Moir, C. C. Morton, C. E. Seidman, J. G. Seidman and D. R. Smith). John Wiley & Sons, New York.
41. Toole, J.J., Pittman, D.D., Orr, E.C., Murtha, P., Wasley, L.C. & Kaufman, R.J. (1986) A large region (∼95kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proceedings of the National Academy of Sciences of the United States of America, 83, 5939-5942.
42. Wood, W.I., Capon, D.J., Simonsen, C.C., Eaton, D.L., Gitschier, J., Keyt, B., Seeburg, P.H., Smith, D.H., Hollingshead, P., Wion, K.L., Delwart, E., Tuddenham, E.G.D., Vehar, G.A. & Lawn, R.M. (1984) Expression of active human factor VIII from recombinant DNA clones. Nature, 312, 330-336.
43. Xiao, X., Li, J. & Samulski, R.J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. Journal of Virology, 72, 2224-2232.
44. Yolov, A. & Shabarova, Z. (1990) Constructing DNA by polymerase recombination. Nucleic Acids Research, 18, 3983.